false 0001305253 0001305253 2024-01-18 2024-01-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2024

 

 

EIGER BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36183   33-0971591

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Eiger BioPharmaceuticals, Inc.

2155 Park Blvd.

Palo Alto, California 94306
(Address of principal executive offices, including zip code)

(650) 272-6138

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   EIGR   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Named Executive Officer

On January 18, 2024, Eldon Mayer III notified Eiger BioPharmaceuticals, Inc. (the “Company”) of his resignation as the Company’s Chief Commercial Officer, to be effective February 2, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Eiger BioPharmaceuticals, Inc.
Dated: January 24, 2024    
  By:  

/s/ James Vollins

    James Vollins
    General Counsel, Chief Compliance Officer & Corporate Secretary
v3.23.4
Document and Entity Information
Jan. 18, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001305253
Document Type 8-K
Document Period End Date Jan. 18, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-36183
Entity Tax Identification Number 33-0971591
Entity Registrant Name Eiger BioPharmaceuticals, Inc.
Entity Address, Address Line One Eiger BioPharmaceuticals
Entity Address, Address Line Two Inc.
Entity Address, Address Line Three 2155 Park Blvd.
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94306
City Area Code (650)
Local Phone Number 272-6138
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol EIGR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Eiger BioPharmaceuticals (NASDAQ:EIGR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Eiger BioPharmaceuticals Charts.
Eiger BioPharmaceuticals (NASDAQ:EIGR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Eiger BioPharmaceuticals Charts.